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Human transmissible spongiform encephalopathies (TSEs) or prion diseases are a group of fatal 
neurodegenerative disorders that include Kuru, Creutzfeldt-Jakob disease, Gerstmann-Sträussler-
Scheinker syndrome (GSS), and fatal familial insomnia. GSS is a genetically determined TSE caused 
by a range of mutations within the prion protein (PrP) gene. Several animal models, based on the 
expression of PrPs carrying mutations analogous to human heritable prion diseases, support that 
mutations might predispose PrP to spontaneously misfold. An adapted Protein Misfolding Cyclic 
Amplification methodology based on the use of human recombinant PrP (recPMCA) generated different 
self-propagating misfolded proteins spontaneously. These were characterized biochemically and 
structurally, and the one partially sharing some of the GSS PrPSc molecular features was inoculated 
into different animal models showing high infectivity. This constitutes an infectious recombinant 
prion which could be an invaluable model for understanding GSS. Moreover, this study proves the 
possibility to generate recombinant versions of other human prion diseases that could provide a further 
understanding on the molecular features of these devastating disorders.
Transmissible spongiform encephalopathies (TSEs) or prion diseases are a group of rare progressive neurodegen-
erative disorders distinguished by long incubation periods and often associated with severe spongiform vacuo-
lation of the central nervous system and neuronal loss1. The causative agent of TSEs is an aberrantly folded prion 
protein (PrPSc) which transforms the normal cellular prion protein (PrPC) into a transmissible isoform2. These 
diseases have been described in a wide range of mammalian species including humans. Human prion diseases 
can be classified into three different types according to their causal origin, sporadic (putatively spontaneous), 
acquired and hereditary or familial3, 4. Sporadic human prion diseases are the result of apparent spontaneous 
misfolding of the PrPc in an individual and includes sporadic Creutzfeldt-Jakob disease (sCJD)5. The acquired 
prion diseases arise from an exposure to disease-associated prions, Kuru and variant of Creutzfeldt-Jakob disease 
(vCJD) are examples of this.
Familial or genetic prion diseases constitute approximately 10% of human prion diseases and are associ-
ated with a range of dominantly inherited mutations within the open reading frame (ORF) of the prion pro-
tein gene (PRNP). More than 30 different pathogenic mutations which give rise to specific clinically manifested 
heritable phenotypes have been described to date6 and include: genetic Creutzfeldt-Jakob disease (gCJD)7, 
Gerstmann-Sträussler-Scheinker syndrome (GSS)8 and Fatal Familial Insomnia (FFI)9. Similar to sporadic prion 
disorders, resulting from rare, putatively spontaneous and possibly stochastic conversion or misfolding of the 
PrPC into PrPSc, it is thought that genetic prion disorders may result from an increased likelihood of the mutated 
protein to misfold spontaneously (absence of exogenous PrPSc) into the aberrant isoform. Thus, disease-associated 
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mutations within the PrP could be potentially considered protein-risk factors that enhance the probability of a 
PrP to misfold spontaneously.
In general, genetic prion diseases seem to be less transmissible in animal models than sporadic prion dis-
eases10 but this may be dependent on the animal model used11. For instance, while studies performed in primates 
showed that brain samples from people affected by GSS A117V mutation were poorly transmissible12, inoculation 
of the same material into transgenic mice expressing human 117V PrP resulted in clinical disease with neuro-
pathological features of prion disease and the presence of PrPSc in the brains of the recipient transgenic mice13. 
However, Pirisinu et al. demonstrated that GSS prion strains associated with different mutations showed low 
transmissibility in general and was dependent on the presence in the inoculum of a classical PrPSc pattern by 
Western Blot after proteinase-K treatment as opposed to containing only lower molecular weight (Mw) “atypical” 
PK-resistant fragments14. The phenotypical variability observed for prion disorders caused by PrPs with slightly 
different amino acid sequence or even by misfolded PrPs with identical primary structure has been used to define 
the prion strain concept. Biochemically, prion strains appear to be slightly different stable conformations or iso-
form of PrPSc, what affects the biochemical (i. e. electrophoretic migration pattern or protease resistance) and 
biological properties (i. e. transmissibility, incubation periods, clinical signs or affected brain regions) of each 
particular prion15, 16.
Although it is accepted that pathogenic mutations make PrP more prone to misfolding, the intrinsic mecha-
nism by which each mutation is responsible for the development of different prion diseases with specific clinical 
profiles and pathogeneses is still unknown.
During the last two decades several transgenic models have been generated by integrating mutations in the 
PRNP which are linked to different human genetic prion diseases. However, most of these models were not able 
to mimic all of the features of a TSE. While the mutated PrPs expressed in these animals exhibited an increased 
tendency to misfold, most of them showed no transmissibility. Hsiao et al. first, and Telling et al. later, used the 
most common mutation found in GSS patients, P102L, to generate a transgenic mouse model able to develop a 
prion disease spontaneously. In both cases, although when the mutant PrP-101L (numbering adapted to mouse 
PRNP gene) was overexpressed the animals resulted in prionopathy-related neurodegeneration, transmission of 
disease via brain homogenates from diseased animals to wild-type animals was not achieved. These results are 
consistent with the pathological process observed in GSS syndrome where infectivity is uncertain17, 18. Manson 
et al. generated further transgenic mouse lines using the same mutation and knock-in technique but expressed 
only physiological levels of P101L mutated mouse PrP. However, these mice did not develop any spontaneous TSE 
during their lifespan19. By contrast, the transgenic mouse model generated by Torres et al., which overexpressed 
by 6-fold the level of bovine PrP protein with the P113L mutation, the bovine equivalent to the P102L human 
mutation, developed fatal spontaneous prion disease. Injection of brain homogenates from the diseased animals 
transmitted disease to transgenic mice that expressed wild-type bovine PrP but with longer incubation periods 
and lower attack-rate than expected20.
Other mutations linked to genetic human prion diseases were also used to generate transgenic mouse models. 
For instance, the E200K mutation was introduced into transgenic mice overexpressing a chimeric mouse/human 
PrP protein which developed a neurodegenerative disease. Inoculation of brain extracts from these clinically dis-
eased mice readily induced a distinct fatal prion disease in wild-type mice21. Jackson et al. engineered knock-in 
mice to express a D178N mutated PrP. These mice spontaneously developed a clinical disease with certain char-
acteristics of FFI and this unique pathology was transmitted from these mice to mice expressing wild-type PrP22. 
By contrast, transgenic mice with the same mutation generated by Bouybayoune et al. accumulated a misfolded 
form of the mutated PrP in their brains and developed a clinical neurological disease with severe sleep disruption, 
highly reminiscent of FFI. However, no prion transmission was detected by bioassay or by protein misfolding 
cyclic amplification (PMCA)23.
The use of recombinant PrP to create recombinant infectious prions started with the generation of the first 
synthetic prions by Legname et al.24. This was followed by many other studies which always used rodent PrP 
(mouse or hamster) and a great diversity in the methods the recombinant prions were prepared which resulted 
inevitably in a variety of strains and attack rates25–30. In 2010, a seminal study changed the way recombinant pri-
ons were accepted in the prion field. Ma et al. developed a new methodology based on PMCA where the mouse 
recombinant PrP, supplemented with RNA and lipids, was able to be converted into a recombinant prion protein 
exhibiting almost identical properties to those generated in vivo in mammals31, 32.
Here, taking advantage of our experience with brain-PMCA, we show the use of a new in vitro propagation 
method, based on recombinant human PrP complemented with PRNP knock-out (Prnp0/0) brain homogenate 
(recPMCA), which has allowed us to generate a spontaneous and transmissible recombinant prion. Several differ-
ent mutated human recombinant PrPs were subjected to serial recPMCA which resulted in a variety of different 
spontaneously misfolded human PrPs displaying distinct properties.
Results
Selection of amino acid substitutions associated with genetic human TSEs to evaluate their 
role in protein misfolding. A total of 9 amino acid substitutions in the human PRNP gene associated with 
the most frequent genetic human TSEs (GSS, gCJD and FFI) were selected in order to evaluate their effect on pro-
tein misfolding. The mutations were accompanied by methionine or valine polymorphism at codon 129 (129M 
or 129V), which might determine the clinical features and pathogenesis. In addition to these known natural 
mutations, several combinations of substitutions/polymorphisms not previously described were also included for 
a better understanding of these diseases. All the selected amino acid changes and 129V or 129M variations are 
described in Supplementary Table 1.
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The bacterially-expressed human recombinant proteins (rec-PrPs) containing the different substitutions were 
purified using a specific protocol (see Methods). The quality of the human recombinant proteins was assessed by 
Coomassie blue staining of SDS-PAGE gels (Supplementary Figure 1) and by MALDI-TOF (data not shown).
Spontaneous generation of human recombinant misfolded proteins. Protein Misfolding Cyclic 
Amplification (PMCA) was first designed to amplify infectious misfolded PrP (PrPSc) from TSE-infected brain 
homogenates as template and from normal brain homogenates as a source of PrPC33. Recently however, de novo 
formation of infectious prions using either purified PrPC or rec-PrP in the presence of facilitating factors, have 
been achieved using a standard or an adapted version of brain-PMCA31.
In order to study which amino acid substitutions played a role in increasing the proneness of PrP to spon-
taneous misfolding, we used a new in vitro propagation method based on recombinant human PrP comple-
mented with Prnp0/0 mouse brain homogenate (recPMCA). Duplicates of four or six tubes containing a variety 
of unseeded recombinant substrates (human gTSE-mutated rec-PrPs + Prnp0/0 mouse brain homogenates) were 
subjected to serial rounds of recPMCA. After each round, 10 μl of the amplified product were transferred to a 
tube containing 50 μl of fresh unseeded substrate and subjected to a new round of recPMCA. All the samples were 
subjected to two independent sets of 30 rounds. The number of total rounds was chosen based on our previous 
experience showing that 20–25 rounds of recPMCA do not change the results when other rec-PrPs (hamster, 
bank vole, sheep, deer and mouse) are managed using a similar procedure (data not shown). The number of 
rounds required to generate spontaneously recombinant prions varied depending on the amino acid substitution, 
showing that not all the mutations were equally effective at increasing proneness of PrP to misfolding (Fig. 1).
The variability observed in some cases in the round number of spontaneous occurrence of the misfolding 
event in inter-experimental and in intra-experimental duplicates (Fig. 1) is likely due to the stochastic process of 
the formation of aggregation nuclei, prior to the formation of misfolding protein aggregates. This phenomenon is 
Figure 1. Spontaneous generation of human misfolded recombinant proteins. Graphical representation of the 
emergence of spontaneous protein misfolding evaluated through Western blot analysis in SDS-PAGE for each 
round of recPMCA (outlined as R01–R30). Different human recombinant proteins were grouped according to 
the substitution and the polymorphism at codon 129 and according to the disease [genetic Creutzfeldt-Jakob 
disease (gCJD), Gerstmann-Sträussler-Scheinker syndrome (GSS) and Fatal Familial Insomnia (FFI)] with 
which they are associated. Every experiment contained 4–5 tubes (intra-experimental replicates) and was 
performed in duplicate as shown. The percentage of positive tubes (tubes showing a protease resistant signal 
after digestion with 80 μg/ml of PK) after each round of recPMCA was noted with different intensities of grey, as 
shown in the legend below the figure. WT: wild type human rec-PrPs.
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common for many other species rec-PrPs (data not shown). The results observed in vitro might correlate well with 
those observed in vivo where human carriers of the same mutation (including cases in identical twins) may show 
variations in the onset of clinical signs of the genetic disease by as much as decades34, 35.
While none of the polymorphic versions (129M and 129V) of the wild type human rec-PrP showed a tendency 
to misfold, five out of nine mutated rec-PrPs (P102L, P105L, A117V, D178N and V210I) showed spontaneous 
misfolding with at least one of the position 129 polymorphic variants (Fig. 1). Surprisingly, the mutated rec-PrPs 
that showed a major proneness to misfold (P105L-129M and A117V-129M) were those containing a mutation/
polymorphism combination that has not been described previously in humans.
A biochemical study by Western blot performed using the GSS-associated mutated rec-PrPs, subjected to up 
to 30 rounds of recPMCA, showed a band of approximately 17 kDa corresponding to the PK-resistant residues 
90–230 fragment of the protein (Fig. 2A). In contrast, recPMCA treated or untreated human wild type rec-PrPs 
resulted in complete digestion after PK treatment (data not shown). All the undigested recombinant proteins 
showed an identical single band of 20–21 kDa corresponding to the full size of the protein (Fig. 2B). The smaller 
size of the PK-digested bands compared to the unglycosylated bands present in the sCJD sample used as control 
is a consequence of the absence of the GPI anchor in the rec-PrPs.
Biochemical characterization of human GSS-associated misfolded rec-PrPs. The following study 
was focused on the most representative substitutions of GSS syndrome: P102L substitution linked to methionine 
or valine polymorphisms at position 129 and the A117V substitution, described in GSS cases associated with the 
valine polymorphism at position 129. A117V substitution associated to the methionine polymorphism has not 
been described in nature as responsible for the GSS syndrome; however, its inclusion in this study was considered 
of interest due to its ability in vitro to spontaneously misfold.
To evaluate the existence of misfolded rec-PrP variants among the four misfolded recombinant proteins their 
PK-resistance and in vitro propagation abilities were compared.
Figure 2. PK-resistance assay of in vitro generated GSS-associated misfolded rec-PrPs. Western blot 
representing the spontaneously generated, misfolded, human rec-PrP after PK-digestion (A) and human (wild 
type and mutated) rec-PrPs based on PMCA substrates (B). Brain homogenates from three human TSE affected 
patients are included as controls: GSS P102 129V, GSS A117V 129V and sCJD MM1. Samples were digested 
with 12, 25 and 85 μg/ml of PK, respectively. The PK digestion (25 μg/ml) of the misfolded recombinant samples 
show a band of approximately 17 kDa corresponding to the PK-resistant 90-230 fragment of the protein (→). 
The recPMCA round from where each seed was scaled up: P102L 129M rPrPres round 24, P102L 129V rPrPres 
round 25, A117V 129M rPrPres round 16, A117V 129V rPrPres round 21, P105L 129M rPrPres round 30, P105L 
129V rPrPres round 30, D178N 129V rPrPres round 30 and V210I 129M rPrPres round 30. Membranes were 
developed with 3F4 monoclonal antibody (1:10,000). Mw: Molecular weight. Despite all the samples shown 
were run in the same gel, the blot was cropped as indicated by the vertical grey line to avoid displaying unrelated 
samples run between the ones shown.
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PK-resistance assay of the in vitro generated GSS-associated misfolded rec-PrPs. The difference in PK-resistance 
exhibited by the variety of described human prion strains led us to evaluate the four different GSS-associated 
misfolded rec-PrPs obtained after 30 rounds of recPMCA. PK-resistance was evaluated by subjecting them to 
increasing concentrations of PK throughout 3 independent experiments. Specifically, the samples were treated 
for 1 h at 42 °C with 12.5, 25, 50, 100, 200, 400, 800, 1600 and 3200 μg/ml of PK and signal detection was evaluated 
by immunodetection of Western blots (Supplementary Figure 2A) and densitometric analysis (Supplementary 
Figure 2B). All misfolded proteins showed a high resistance to PK digestion (up to 800–1600 μg/ml) with the 
exception of the A117V-129V misfolded protein whose PK-resistance was slightly but not significantly lower 
(200–400 μg/ml) (Supplementary Figure 2A). These results were confirmed after densitometric analysis of the 3 
independent replicates (Supplementary Figure 2B).
In vitro propagation-ability study of the in vitro generated GSS-associated misfolded rec-PrPs. One of the main 
features of disease-associated prions is their ability to self-perpetuate by continued replication in vivo36. Therefore, 
after having determined that in vitro spontaneously misfolded prion proteins fulfil the main characteristic of 
being resistant to PK, we proceeded to test their ability to replicate as this property could be a good comparative 
marker of potentially distinct misfolded recombinant PrP variants generated spontaneously. Serial dilutions of 
the misfolded prion proteins under study (namely, seed) were submitted to a single 48 h round of recPMCA. The 
amount of PK-resistant misfolded protein in the seed was adjusted trying to maintain similar concentrations 
(Fig. 3A). Similarly, the concentrations of the recombinant proteins from different substrates were adjusted using 
the BCA Protein assay and subsequent verification by Western blotting (Fig. 3A). Each of the GSS-associated 
misfolded rec-PrPs was subjected to serial dilutions in the substrate containing their respective rec-PrPs (same 
substitution and polymorphism at codon 129). The dilutions employed ranged from 10−1 to 10−8. 10−1 and 10−2 
dilutions that were not subjected to recPMCA were used as a reference for the signal derived from the initial seed 
prior to amplification (Fig. 3B). Despite the seed normalization performed (Fig. 3A), there are apparent differ-
ences in the non-amplified samples of each seed (Fig. 3B), in part due to the variability across different Western 
blots. However, the high sensitivity of the recPMCA allows to overcome the differences observed in seed input 
and the normalization performed has been considered sufficient to evaluate significant differences on the propa-
gation ability of each seed used.
The seeds containing P102L substitution with either polymorphic variants at codon 129 were able to amplify 
up to a 10−8 dilution. However, the misfolded A117V-129M rec-PrP used as seed showed 100 times less replica-
tion ability, amplifying until a 10−6 dilution. The presence of the valine polymorphism at codon 129 diminished 
the replication capacity showing a decrease of about 1,000 times as compared to its homologous 129M and 105 
times less as compared to the replication capacity of any of the P102L-129V seeds (Fig. 3B).
Figure 3. In vitro propagation ability study of in vitro generated GSS-associated misfolded rec-PrPs. (A) 
Western blot of the four in vitro generated GSS-associated misfolded rec-PrPs used as seed after PK digestion 
(25 µg/ml) (rPrPres) and the four undigested substrates containing the corresponding GSS-associated rec-PrPs 
(rPrP). Note the signal from both, seeds and substrates were similar. The concentration of the recombinant 
proteins that comprised the different substrates was also adjusted using the BCA Protein assay. (B) Western 
blots of amplified samples subjected to a single 48 h round recPMCA (A). Each GSS-associated misfolded rec-
PrPs was subjected to serial dilutions in the substrate containing their respective rec-PrPs (same substitution 
and polymorphism at codon 129). The dilutions employed ranged from 10−1 to 10−8. 10−1 and 10−2 dilutions 
without undergoing recPMCA were used as controls of the signal derived from the initial seed prior to 
amplification (NA). All samples were digested with 25 µg/ml of PK. The seeds containing the P102L substitution 
with either polymorphic variants at codon 129 were able to amplify until at least 10−8 dilution. However, 
the misfolded A117V-129M rec-PrP showed 100 times less in vitro propagation ability, amplifying up to a 
10−6 dilution. Moreover, misfolded A117V-129V rec-PrP amplified just up to a 10−3 dilution. PK-untreated 
recombinant proteins were used as control (GSS rPrP). 3F4 monoclonal antibody (1:10,000) was used for 
visualisation. Mw: Molecular weight.
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Structural characterization of human GSS-P102L-129M misfolded rec-PrPs. In order to further 
characterize a human misfolded rec-PrP from among the four GSS-associated misfolded rec-PrPs, we selected 
GSS-P102L-129M as it is the most common mutation/polymorphism of this neurodegenerative syndrome. The 
misfolded recombinant protein was propagated in vitro on a substrate devoid of other proteins or contaminants 
that would impede its correct visualization by electron microscopy. Thus, the misfolded P102L-129M rec-PrP 
was propagated by serial rounds of recPMCA on a substrate containing only conversion buffer and RNA as 
propagation-helper cofactor. The initial seed, containing Prnp0/0 brain homogenate, was serially diluted tenfold 
up to a total of 15 rounds (10−16 final dilution of the initial seed). The number of rounds applied was based on a 
mathematical calculation using Avogadro’s number which ensures that a dilution of 1016 leads to complete dis-
appearance of all molecules of misfolded rec-PrP from the initial seed37. This procedure also ensured obtaining 
a clarified sample ready for further characterization. RNA was used because it has been previously described as 
a competent propagation cofactor31 and would allow the direct observation of the ultrastructure of misfolded 
rec-PrP whose general appearance should be like the one of the seed obtained in Prnp0/0 brain homogenate, since 
the rods in our preparation resemble the ones obtained from GPI-less PrP expressing mouse prions. However, 
slight variations in other biochemical or biological properties that could result from its propagation in the 
RNA-complemented substrate were not further investigated. The analysis of this sample after treatment with PK 
by SDS-PAGE and Coomassie blue staining showed the presence of a ∼17 kDa band, which is equivalent to the 
classic ∼90–230 PK-resistant fragment termed PrP27–30 in glycosylated, GPI-containing brain-derived PrPSc; 
additionally, a group of bands with apparent Mws of ∼7–10 kDa and a slightly higher intensity were detected, 
matching the molecular weight of the unglycosylated and PK-resistant fragments observed in the brain-derived 
material in GSS (Fig. 4A, and data not shown). Epitope mapping with the 12B2 antibody, which recognizes 
epitope 90–9238 showed that at least two of the ∼7–10 kDa bands contain this epitope, which, considering their 
size, means they must be the result of a double N-, C-truncation (Fig. 4B).
Transmission electron microscopy. Negative stained, TEM images of misfolded P102L-129M rec-PrP, previously 
propagated over an RNA based substrate, showed short rod-like structures (Fig. 5A) whose general appearance 
resembles that of GPI-anchorless PrPSc and wild type PrPSc samples isolated from prion-infected brains39. Often, 
the individual fibrils making up the rods could be discerned; they were ∼10 nm wide and composed of two inter-
twined protofilaments (red arrow in Fig. 5A). Fibrils featuring parallel protofilaments were also seen (blue arrow 
in Fig. 5A). Similar fibrils have been detected in brain-derived prion preparations40. Besides the fibrils and rods, 
some amorphous material was also seen that might correspond to fibrils shattered during the sonication steps of 
PMCA. Finally, rosette-like structures (red circle in Fig. 5A) were present similar to those described by Piro et 
al. in preparations of highly infectious recMoPrPSc41. These rosettes are glycogen from RNA liver extracts used 
to prepare these misfolded rec-PrP samples and disappeared upon treatment of the samples with glucogenase 
(data not shown and ref. 42). To definitively rule out the possibility of the rosettes being composed of rec-PrP, 
Figure 4. PK-resistant fragment pattern of GSS-associated misfolded P120L-129M rec-PrP. Misfolded P120L-
129M rec-PrP prepared with KO brain-supplemented PMCA was digested with 25 µg/ml PK for 1 h at 42 °C (see 
main text for details). PK-digested samples were subjected to tris/tricine SDS-PAGE. The gel was subjected to 
(A) Coomassie blue staining showing the presence of a ∼17 kDa band, which should correspond to the classic 
∼90–230 PK-resistant fragment and a group of bands with apparent Mws of ∼7–10 kDa, or (B) blotted to a 
PVDF membrane that was probed with antibody 12B2 (which recognises residues 90–92) showing that at least 
two of the ∼7–10 kDa bands might be the result of a double N-, C-truncation.
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Figure 5. Electron microscopy analysis of misfolded P120L-129M rec-PrP. (A) Negative stain TEM images of 
misfolded P102L-129M rec-PrP. Samples were deposited in freshly glow-discharged carbon-coated gold grids and 
stained with 5% uranyl acetate. Short rod-like structures (left images), exhibit a close resemblance to those observed 
in RML GPI-anchorless PrPSc (right images). In both cases images show bundles of laterally associated fibrils 
(“rods”); in many instances, the individual fibrils that by association make up the rods can be discerned. As previously 
reported in many previous studies, these fibrils are ~10 nm wide and in turn composed of two intertwined individual 
protofilaments (an example is signalled with a red arrow). At times, the two individual protofilaments run parallel 
in a short stretch of the fibril (blue arrow). Amorphous material corresponding likely to fibrils shattered during the 
PMCA was also present. Rosette-like structures made of glycogen, present as an impurity in the RNA used as a co-
factor for generation of the recombinant PrP are also observed (red circles). (B) Cryo-EM images of the misfolded 
P102L-129M rec-PrP. The sample was concentrated 100 times by sedimentation after PK digestion (100 µg/ml). Short 
rod-like structures of 100 to 200 nm in length are present. Rosette-like structures containing glycogen are also shown 
(red circles). As in TEM images, fibrils in the misfolded rec-PrP preparations showed a high resemblance to those 
observed in the purified PrPSc sample from brains of GPI-anchorless transgenic mice inoculated with RML prion 
strain (right images): in both cases, the basic element is a ~10 nm fibril made up of 2 intertwined protofilaments. In 
images of GPI-anchorless PrPSc (right), dark dots are 15 nm fiducial gold particles.
www.nature.com/scientificreports/
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a substrate prepared with RNA but without rec-PrP was submitted to the same concentration procedure and 
observed by cryoEM, which showed exactly the same rosettes (Supplementary Figure 6).
Electronic cryo-microscopy (cryo-EM). The misfolded P102L-129M rec-PrP sample was concentrated 100 times 
after PK-digestion (100 μg/ml) and was processed for cryo-EM visualization. Misfolded P102L-129M rec-PrP was 
observed as small fibrils or short rod-like structures of 100 to 200 nm in length (Fig. 5B, left images). As in the 
TEM images, rosettes structures containing glycogen are also seen (Fig. 5B, red circles in the left image). Fibrils 
in the misfolded rec-PrP preparations showed a high resemblance to those observed in the GPI-anchorless PrPSc 
sample purified from RML inoculated GPI-less transgenic mouse brains (Fig. 5B, right images). In both cases, 
rods consist in bundles of laterally-associated ∼10 nm fibrils; in turn, each fibril consists of two intertwined 
protofilaments.
In vitro propagation of human GSS-associated misfolded rec-PrP conformations to human wild 
type proteins. Prion strains are principally characterized by their differential ability to be propagated in cer-
tain biological contexts e.g. different PrP species or polymorphic variants of the same PrP43. In order to determine 
if the four biochemically similar GSS-misfolded rec-PrPs differed in their ability to propagate in vitro in the same 
substrate they were subjected to two different assays (serial dilutions of each seed submitted to a single recPMCA 
round and serial rounds of recPMCA) in which the substrates were based on the corresponding wild type human 
(129M or 129V) rec-PrPs.
In the first experiment, misfolded rec-PrPs were subjected to a single round of recPMCA using a serial dilu-
tion of each GSS-associated misfolded rec-PrP as seed and a substrate based on wild type human rec-PrP. The 
substrates were prepared using recombinant proteins carrying the same 129 polymorphism as the seeds. The 
amounts of protein used as starter seeds or present in the substrates were adjusted to ensure the results were 
comparable (Fig. 3A). None of the seeds were able to propagate in vitro in a wild type human recombinant pro-
tein substrate in a single recPMCA round (Supplementary Figure 3). In some cases, the signal observed in the 
10−1 dilution after recPMCA was comparable to the signal obtained in the same dilution of the seed without 
being subjected to recPMCA. These results suggest the existence of a significant polymorphism barrier which 
is a well-known feature of prion strains44 and impedes the propagation in a single recPMCA round in this case.
Experimental in vivo studies have demonstrated that most of the prion strains can be adapted after serial 
passages in individuals carrying different polymorphic variants of PrP. To address whether this intrinsic feature, 
associated with the concept of PrP strain, was conserved in some of the GSS-associated misfolded rec-PrPs gener-
ated spontaneously in vitro, a serial recPMCA was performed. An experimental design similar to that used in the 
previous one-round study was carried out subjecting the same combinations of seed/substrate to serial recPMCA. 
Identical quadruplicates were subjected to a total of 10 rounds of recPMCA where a 1:10 dilution of the seed was 
refreshed in a new substrate for each round. Four unseeded tubes containing wild type human rec-PrP were used 
as a control to show there was no cross-contamination during the experimental procedure.
While the misfolded P102L-129V and A117V-129V rec-PrPs were unable to propagate over the wild type 
human 129V rec-PrP after 10 rounds, the misfolded P102L-129M and A117V-129M rec-PrPs required just 
3 to 5 rounds, respectively, to propagate over the wild type human 129M rec-PrP (Fig. 6). Once adaptation 
occurred, propagation was maintained indefinitely (more than 30 rounds; data not shown). The absence of 
Figure 6. In vitro propagation of human GSS-associated misfolded rec-PrPs to human wild type recombinant 
proteins. GSS-associated misfolded rec-PrPs were subjected to serial rounds of recPMCA (R1–R10) in 
quadruplicate. A representative experiment for each round is shown after PK (25 µg/ml) digestion of the 
samples. Tubes containing wild type human rec-PrP (129M and 129V) without any seed were used as control 
for cross-contamination. Misfolded P102L-129M and A117V-129M rec-PrPs required just 3 to 5 rounds, 
respectively for an entire adaptation to the wild type protein. However, misfolded P102L-129V and A117V-
129V rec-PrPs were unable to propagate over the wild type human 129V rec-PrP after 10 rounds of recPMCA. 
No PK-resistant signals in any of the unseeded samples suggests complete absence of cross-contamination. 3F4 
monoclonal antibody (1:10,000) was used. Mw: Molecular weight.
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PK-resistant signals in any of the unseeded wild type human recombinant proteins shows complete absence of 
cross-contamination (Fig. 6).
In order to exclude that the inability of GSS-associated misfolded 129V rec-PrPs to propagate over a wild 
type human 129V rec-PrP based substrate was due to an incapability of the substrate to propagate any human 
recombinant seed, two different experimental approaches were performed (Supplementary Figures 4 and 5). 
Their incapacity to propagate in wild type human 129M rec-PrP substrate (Supplementary Figure 4) as well as 
the ability of wild type human 129V rec-PrP based substrate to propagate other human GSS-associated misfolded 
rec-PrP seeds (Supplementary Figure 5) suggest that the inability of GSS 129V misfolded rec-PrPs to propagate 
was probably due to their intrinsic characteristics.
In vitro propagation of human GSS-associated misfolded rec-PrPs by brain-PMCA. Although 
different human misfolded rec-PrPs were spontaneously generated and some of them showed differential bio-
chemical properties similar to those in prion strains, prions are principally characterized by their ability to prop-
agate in brains, i.e. to be infectious. Therefore to classify appropriately these misfolded proteins as recombinant 
prions, evidence of propagation in brain tissue would be required. For this reason we wanted to evaluate first the 
abilities of the human GSS-associated misfolded rec-PrPs to propagate in vitro in brain homogenates prepared 
from two different animal models: Tg340 and TgNN6h mice. Both transgenic mouse models express human 
129M PrP but with notable differences in glycosylation. While the Tg340 model overexpresses human PrP with 
the three possible glycosylation forms (mono- di- and unglycosylated)45, the TgNN6h model expresses only the 
unglycosylated protein46. GSS P102L-129M misfolded rec-PrP was selected because it is the mutated protein 
that appears most frequently in cases of GSS and contains the same 129 polymorphism that the human PrPC 
which is expressed in both mouse models. The misfolded protein used as seed was subjected to 3 serial rounds 
of brain-PMCA using brain homogenates from Tg340 mice versus brain homogenates from TgNN6h mice. The 
study was performed in quadruplicates and unseeded samples for each brain-based substrate were used as neg-
ative controls.
GSS P102L-129M misfolded rec-PrP was unable to propagate the misfolding of the Tg340-derived human 
PrPC despite a nearly identical amino acid sequence between both proteins (Fig. 7A). The serial propagation 
experiment using the same substrate was continued until round 5 with negative results. To ensure that Tg340 
was a suitable substrate for in vitro prion propagation, a human control inoculum of sporadic Creutzfeldt-Jakob 
disease (sCJD) was used as seed and subjected to a single round of brain-PMCA after dilution. A PrPres amplifi-
cation of around 102–103-fold demonstrated the aptness of the Tg340-based substrate (Supplementary Figure 7). 
This inability to propagate of the recombinant seed correlated with the GSS brain-derived seed. To rule out the 
possibility that P102L amino acid mismatch is responsible for the lack of propagation in Tg340, the misfolded 
P102L-129M seed propagated in human wild type 129M rec-PrP was also tested to propagate in Tg340 by serial 
PMCA rounds. This seed, without any amino acid mismatch with the Tg340 PrP, was also unable to propagate 
in 10 PMCA rounds, excluding the possibility of inhibition due to the amino acid mismatch (data not shown). 
By contrast, the same misfolded rec-PrP was propagated efficiently (all replicates showed the same result) in the 
unglycosylated human protein (TgNN6h-derived PrPC). A PK-resistant fragment of approximately 20 kDa in 
contrast to the approximately 17 kDa of the seed suggests the existence of a GPI anchor as a standard characteris-
tic of prions propagated in brain-derived substrates.
Unseeded samples from both substrates, used as negative controls, remained negative until at least 5 PMCA 
rounds suggesting the absence of spontaneous misfolding or cross-contamination.
The efficient ability of GSS P102L-129M misfolded rec-PrP to be propagated in an unglycosylated form of 
human PrPC, comparable to the GSS brain-derived PrPSc, led us to evaluate more accurately the propagation 
capacity of the four GSS-associated misfolded rec-PrPs using a TgNN6h brain-derived substrate. The exper-
iment was performed similarly to the previous one including 4 seeds (P102L-129M, P102-129V, A117V-
129M and A117V-129V misfolded rec-PrPs) and the serial brain-PMCA was performed for up to 10 rounds. 
As described previously, each seed was tested in quadruplicates and four unseeded samples of TgNN6h brain 
homogenate were used as negative controls (Fig. 7B).
Three GSS-associated misfolded rec-PrPs including both polymorphic variants of P102L and the A117V-129M 
required only three rounds of brain-PMCA for stable propagation in the unglycosylated substrate. In contrast, the 
A117V-129V misfolded rec-PrP needed 10 rounds of serial PMCA to be propagated. The whole experiment was 
repeated twice with identical results. These results indicate, again, that the four misfolded rec-PrPs behaved differ-
ently suggesting the existence of different types of misfolded rec-PrPs, most likely conformational variants, which 
may present different biochemical and biological properties due to slightly distinct conformations (Fig. 7B).
Infectivity of GSS-associated misfolded rec-PrPs in two different transgenic mouse mod-
els. The infectivity of brain samples from GSS-affected patients depends on the animal model that is used. 
While transmission studies performed on primates suggested a very low infectivity12, the use of bank voles 
(Myodes glareolus) as a model has completely changed the “low-infectious” perception of this atypical prion11.
We used GSS P102L-129M rec-PrP spontaneously misfolded in vitro to evaluate its infectious properties. A 
sample was inoculated in two different animal models: Tg340 (transgenic mouse overexpressing human PrPC)45 
and Tga20 (transgenic mice overexpressing mouse PrPC)47. While the relevance of the first model is obvious 
since we wished to evaluate the infectivity of a human misfolded rec-PrP, the use of Tga20 responds to unpub-
lished studies showing this model was suitable to study the infectivity of GSS samples (Andreoletti O; personal 
communication).
While the transgenic mouse model overexpressing human PrP was unable to propagate either brain-derived 
or misfolded rec-PrPs inocula (at least by the first passage), Tga20 mice succumbed showing principally lethargy 
and progressive cachexia at 506 ± 30 dpi and 297 ± 37, respectively (Table 1), with a duration of the disease of 2–3 
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weeks, similar in both groups. The histopathological study revealed slight vacuolation in the hippocampus and 
cerebral cortex, while moderate vacuolar lesions were observed in the cerebral peduncle. No vacuolar changes 
were observed in age matched non-inoculated mice. A similar high attack rate and indistinguishable clinical signs 
argue in favor that both samples triggered a similar prion disease in Tga20 mice. Taking the in vivo GSS inoculum 
as control to interpret the results of infectivity in each of the transgenic mouse models, the GSS-related misfolded 
rec-PrP might be considered at least as infectious as the brain-derived sample, based on their high attack rates. 
The difference observed in incubation periods may respond to the different origins of both inocula, since it has 
Figure 7. In vitro propagation of human GSS-associated misfolded rec-PrPs by brain-PMCA. (A) The GSS P102L-
129M misfolded rec-PrP was selected as the seed to be subjected to 3 serial rounds of brain-PMCA using brain 
homogenates from Tg340 mice or TgNN6h mice as substrates. A brain homogenate from a GSS P102L-129M 
affected patient was used as control seed. The study was performed in quadruplicates and unseeded samples for 
each brain-based substrate were used as negative controls. Neither the GSS P102L-129M misfolded rec-PrP nor 
the GSS brain-derived seed were able to propagate the misfolding to the Tg340-derived human PrPC. However, 
the same misfolded rec-PrP was propagated efficiently (see the four positive duplicates) with the unglycosylated 
human protein (TgNN6h-derived PrPC). A PK (at 85 µg/ml) resistant fragment of approximately 20 kDa, in 
contrast to the approximately 17 kDa of the seed, suggests the existence of a GPI anchor as a standard characteristic 
of prions propagated in brain-derived substrates. Unseeded samples from both substrates remained negative 
until at least 5 PMCA rounds suggesting the absence of spontaneous misfolding or cross-contamination. The GSS 
patient control was run in a separate gel and the image shown, divided from the other gel by a vertical grey line, 
was cropped adjusting the size in accordance with the molecular weight markers. (B) The four GSS-associated 
misfolded rec-PrPs were selected as seeds to be subjected in quadruplicate to 10 serial rounds of brain-PMCA 
(R1-R10) using brain homogenates from TgNN6h mice as substrate. A representative experiment for each round is 
shown after PK (85 µg/ml) digestion of the samples. Unseeded tubes containing only TgNN6h based substrate were 
used as control for cross-contamination. Three GSS-associated misfolded rec-PrPs, including both polymorphic 
variants of P102L and A117V 129M, required only 3 brain-PMCA rounds for full adaptation to the unglycosylated 
substrate. In contrast, the A117V-129V misfolded rec-PrP needed 10 serial PMCA rounds to be propagated. 3F4 
monoclonal antibody (1:10,000) was used. Mw: Molecular weight.
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been reported that even prion isolates adapted by PMCA to brain homogenates of the same species caused a 
poorly understood prolongation on incubation periods48.
For biochemical analysis of mouse brain, homogenates from clinically affected animals were digested accord-
ing to a special procedure detailed in Methods. 100% of the samples showed an indistinguishable atypical pattern 
characterized by a multiband pattern of PK-resistant PrP fragments in both groups of inoculated Tga20 mice 
(Fig. 8).
Discussion
Human genetic prion diseases (GSS, FFI and gCJD) are caused by more than 30 different known pathogenic 
mutations. However, the intrinsic mechanisms by which each of these mutations causes prion disease are still 
unknown despite the highly productive advances in generating a diversity of synthetic recombinant prions 
through in vitro misfolding of different wild type rodent PrPs (mouse or hamster) that have taken place in the last 
decade24, 25, 29, 31, 49, 50. Taking advantage of our experience with brain-PMCA, we developed an in vitro method to 
evaluate the susceptibility to misfolding of certain pathogenic mutations in association with the two polymorphic 
variants of the human PrP at residue 129 (M/V). This novel method showed different behaviors between the wild 
type human rec-PrP and the majority of the mutated human proteins. The wild type proteins (129M and 129V), 
used as controls in more than 20 serial recPMCA experiments, were unable to spontaneously misfold. In contrast, 
many of the mutated human proteins misfolded spontaneously in at least one of the serial recPMCA experiments 
performed. These results are in agreement with the low prevalence of these sporadic disorders (1–2 per million 
people) and the high (close to 100%) penetrance observed in most of the genetic prion diseases. This initial step 





Survival time of positive 
animals (dpi) (±SEM) Attack rate PrPres detection rate PrPSc pattern
Misfolded rec-PrP Tg340 Human (4x) 438 – 670 0/12 (0%) 0/12 a —
GSS brain PrPSc Tg340 Human (4x) 671 ± 71 0/12 (0%) 0/12 —
Misfolded rec-PrP Tga20 Mouse (8x) 506 ± 30b 9/10 (90%) 9/10 Atypical
GSS brain PrPSc Tga20 Mouse (8x) 297 ± 37 10/10 (100%) 10/10 Atypical
Table 1. Inoculation of in vivo vs. in vitro GSS-related samples in two different transgenic mouse models. aMice 
were euthanized at different days post-inoculation with non prion-specific clinical sings: 438 (6), 440, 442 (3), 
454 (2) and 540 dpi. The rest of the animals did not show clinical signs up to 670 dpi. None of the brain samples 
were positive by Western blot or immunohistochemistry (IHC). bOne mouse showed intercurrent disease at 102 
dpi and was PrPres negative by Western blot. This animal was not included to calculate the SEM or attack rate. 
One mouse was found dead at 354 dpi without previous clinical signs but clearly PrPres positive. The rest of the 
mice were euthanized at different days post-inoculation with clear signs of prion-related clinical disease: 372, 
384, 501, 511 (2), 547, 582 and 649 (2) dpi. SEM: Standard Error of the Mean. dpi: days post inoculation.
Figure 8. Biochemical analysis of Tga20 mice inoculated with in vivo vs. in vitro GSS-related samples. 
Biochemical analysis of brain homogenates from Tga20 mice inoculated with the in vitro misfolded P102L-
129M rec-PrP and the in vivo isolate from a GSS affected patient. Representative mouse brain homogenates 
from animals inoculated with both in vitro and in vivo samples were digested with 12,5 µg/ml of PK and purified 
according to a special procedure detailed in the Methods. An indistinguishable atypical pattern characterized 
by multiple bands of PK-resistant PrP fragments was observed in both groups of inoculated Tga20 mice. 
Classical sheep scrapie was used as control to show classical pattern. 12B2 monoclonal antibody (1:2,500). Mw: 
Molecular weight. Samples were run in separate gels, as indicated by the blank space between them, and images 
were cropped to not show unrelated samples run in the same gels. Alignment of both cropped blots was done 
according to the molecular weight markers.
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them, at least in vitro in this particular experimental set, were equally predisposed to misfolding. Thus, mutations 
F198S-129V, Y218N-129V, V180I-129M, E200K-129M and D178N-129M rec-PrPs (all previously described in 
human prion diseases) failed to misfold after two complete serial rounds of recPMCA. Although, we cannot rule 
out that further rounds of recPMCA or more duplicates could induce spontaneous misfolding, these results led 
us to conclude that not all the known mutations are equally prone to misfolding. Using recombinant protein 
techniques, we generated prion protein variants that do not occur naturally which allowed us to explore further 
the implications of the polymorphic codon 129 in spontaneous misfolding. In fact, two of the novel recombinant 
mutated proteins (P105L-129M and A117V-129M) showed a clearly higher propensity to misfold than proteins 
with a combination of substitutions/polymorphism described in clinically affected patients.
The spontaneous misfolding process seems to be governed through a stochastic control that likely depends 
on the formation of nuclei51, 52. Frequently, the first misfolding event occurred at different recPMCA rounds in 
each duplicate within the same experiment, and in none of the experimental repetitions did the first spontaneous 
misfolding emerged in the same recPMCA round. The lower the tendency to spontaneous misfolded of a specific 
prion protein (e.g. D178N-129V and 129V-A117V) the more pronounced this characteristic was.
Conversely, for prion proteins that showed a greater propensity to spontaneously misfold (A117V-129M and 
129M-P102L) intra- and inter-experimental differences were minor. However, not all in vitro results correlated 
with the data obtained from human clinical cases. For instance, E200K-129M and V180I-129M mutations, which 
represent the most frequent substitutions found in gCJD affected patients from Europe and East Asia respec-
tively53, did not misfold in this occasion. This behaviour of the E200K-129M prion protein is in agreement with 
the results obtained in vivo using transgenic mice expressing human E200K-129M PrP where spontaneous dis-
ease is difficult to generate in some transgenic mouse lines21, 54, or has not been reported in others (even in ani-
mals of advanced age), despite being highly susceptibility to infection with other specific disease-associated prion 
strains55. In the case of the D178N-129M genotype, which is present in FFI, no misfolding was found yet the same 
mutation within mouse recombinant PrP results in spontaneous misfolding56.
The implications of the M/V polymorphism at position 129 of the prion protein on propagation in vitro and 
in vivo have been widely studied57. Our results suggest that this polymorphism may also be critical to the ability 
of these proteins to spontaneously misfold supporting the theory that some mutations provide enhanced mis-
folding ability when combined with 129M genotype. This different susceptibility to misfold spontaneously was 
particularly evident with the mutations P105L-129V (rounds 19 & >30) versus P105L-129M (rounds 4 & 7) and 
A117V-129V (rounds 19 & >30) versus A117V-129M (rounds 6 & 7).
Of the eight different GSS-associated prion proteins used, all except three (Y218N-129V, F198S-129M and 
F198S-129V) were able to misfold spontaneously in this experimental set. However, the GSS syndrome described 
in patients carrying the Y218N-129V prion protein develops much slowly than other GSS syndromes which may be 
due to a lower natural tendency of this protein to misfold58 and explain our results. In general, the occurrence of mis-
folding observed in most of the mutated prion proteins examined is consistent with the existence of human clinical 
cases and also with the presence of spontaneous misfolding and resultant pathology which developed in transgenic 
mice overexpressing one of these protein variants (P102L-129M, A117V-129V and D178N-129V)18, 19, 59, 60.
In order to perform a more extensive characterization of some spontaneously misfolded prion proteins, those 
more representative of causing the GSS syndrome were selected; P102L and A117V mutant proteins carrying the 
two polymorphisms (129M and 129V). The first general prion-related features shown by the four selected mis-
folded proteins was their high resistance to PK digestion and the resultant unique ∼17 kDa band.
One of the most intriguing prion characteristics is that the same species PrP can spontaneously misfold (or by 
seeding) into numerous different conformations. Although the mechanism of this phenomenon is unknown, it 
seems to be favored by the existence of different mutations in the PrP. For this reason, the four GSS-related mis-
folded prion proteins were analyzed in an attempt to determine the existence of different conformational variants 
using PK-digestion and in vitro propagation studies. In addition to the unexpectedly high PK resistance observed 
in some of the four misfolded proteins (up to 3200 μg/ml), the presence of significant differences between them 
was clear. Similarly, the in vitro studies using the misfolded prion proteins as seeds to evaluate the ability to propa-
gate over their own mutated protein allowed us classify the proteins based on their propagation efficiency: i) high 
efficiency, ii) medium efficiency and iii) low efficiency. The misfolded proteins containing P102L mutation (both 
129M and 129V version) were propagated with high efficiency with differences between the two polymorphisms 
observed. This is consistent with the results of the spontaneous misfolding study where both proteins also showed 
similar results. By contrast, A117V prion protein seeds showed medium or low propagation efficiencies depend-
ing on polymorphisms 129M or 129V, respectively. Again, this correlates with the results observed in the gen-
eration of spontaneous misfolded prion proteins in which human A117V-129V showed a lower propagation 
efficiency compared to its counterpart A117V-129M. Although further characterization is required, these results 
suggest that minimal changes in the protein (a single amino acid) were sufficient to produce structural changes 
during the spontaneous misfolding process giving rise to different prion variants.
In addition to their biological features such as infectivity, prions are also characterized by their structural 
organization. PK has been used traditionally to probe the structure of different PrPSc species. GSS PrPSc yields a 
very characteristic ∼80–150 doubly truncated PK-resistant fragment14, 61, 62. The relative abundance between the 
∼80–150 and ∼80–230 fragments after PK treatment is a characteristic of different types of GSS cases. Treatment 
of misfolded P102L-129M rec-PrP with PK followed by SDS-PAGE resulted in three main PK-resistant bands of 
approximately similar intensity after staining with Coomassie blue dye, corresponding to peptides of Mws of ∼17, 
10 and 8 kDa (Fig. 4). The ∼17 kDa band corresponds to the ∼90–230 PK resistant fragment; and the absence of 
GPI anchor and glycan moieties in rec-PrP results in a single band in opposition to the characteristic PrP27–30 
triplet of di- mono- and non-glycosylated GPI-containing bands seen in GSS cases. Antibody 12B2 (which binds 
to an epitope on amino acid residues 90–92) recognized the ∼17 and ∼8 kDa bands, which means that the lat-
ter must necessarily correspond to the characteristic PK-resistant ∼90–150 fragment that is pathognomonic of 
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GSS cases and appears alongside the ∼80/90–230 triplet. The ∼10 kDa fragment seen in the Coomassie blue 
stained gel was not detected by 12B2, signifying that it might be a C-terminal PK-resistant fragment63. All this 
suggests that the general structure of misfolded P102L-129M rec-PrP might be comparable with that of PrPSc 
found in the brains of natural cases of GSS. Prion isolation from a prion-infected brain typically yields charac-
teristic rod-shaped structures easily seen by electron microscopy (EM). As GPI-anchorless PrPSc mostly consists 
of PrP molecules that lack both the GPI and glycan moieties64, as does the rec-PrP, we reasoned that the quater-
nary structures of purified, misfolded P102L-129M rec-PrP and GPI-anchorless PrPSc samples should be similar 
and cryo-EM images of both samples supported this. In both cases, characteristic ∼10 nm fibrils composed of 2 
intertwined protofilaments were observed and these fibrils were associated laterally to form thicker rods (Fig. 5). 
Overall, our results suggest that the quaternary structure of the misfolded P102L-129M rec-PrP is apparently 
similar to the GPI-anchorless PrPSc.
Our experience using 12 wild type recombinant PrPs from different species is that the human rec-PrP is the 
most difficult protein to spontaneously misfold in vitro (unpublished results). This questioned whether this pro-
tein could be misfolded by induction with an initial seed, and if different GSS-related misfolded prion proteins 
would have different abilities to overcome the mutant/wild type transmission barrier. As prion strains can be 
propagated only in certain species or polymorphic variants as a consequence of the transmission barrier65–67, we 
designed two different studies. The first assessed the ability of the misfolded prion proteins (seeds) to propagate in 
substrates based on the wild type prion protein containing the same polymorphism at position 129. None of the 
seeds were able to propagate efficiently which is in agreement with the in vivo data using different animal mod-
els68. These results corroborate the importance of the primary amino acid structure of the PrP of both the donor 
(seed) and the receptor (substrate) species with respect to propagation of prions65, 69.
The second study was based on the adaptation phenomenon characteristic of most prion strains in vivo and 
that has been observed also in vitro70. Once again, A117V-129M misfolded rec-PrP, which was most permissive 
to the spontaneous misfolding process, was the most efficient protein crossing the barrier to the wild type prion 
protein. However, the most unexpected result was that none of the 129V variants were able to propagate in wild 
type 129V human prion proteins. Since the same wild type human prion protein had been a good substrate to 
propagate other seeds (Supplementary Figure 5) and the same seeds were not able to propagate in the wild type 
129M human prion protein, the only explanation is that those 129V misfolded rec-PrPs constitute different con-
formational variants with a strong transmission/propagation barrier. This surprising result confirmed the impor-
tance of the 129 polymorphism in prion protein propagation.
By definition, a prion is an infectious protein. Thus, to migrate conceptually from “misfolded rec-PrP” to 
“infectious recombinant prion”, we performed different infectivity assays. Taking advantage of brain-PMCA which 
mimics, in an accelerated manner, prion propagation in the brain70, 71, we evaluated the ability of P102L-129M 
misfolded rec-PrP to self-replicate over a brain-derived human wild type 129M PrPC substrate (Supplementary 
Figure 3 and Fig. 6). The first step used brains from transgenic mice overexpressing human wild type PrPC, Tg340. 
Unfortunately, neither brain-derived GSS P102L-129M nor the recombinant version of the same PrP were able to 
convert the human PrPC in vitro after 5 rounds of brain-PMCA. These negative results, together with data show-
ing that misfolded rec-PrP was able to propagate by recPMCA over human wild type rec-PrP, can be explained 
due to the incapacity of GSS prion strains to propagate in vitro over human brain-derived PrP. Until now, no atyp-
ical prion strain (from human or sheep) has been propagated in vitro. Although, we do not know the mechanisms 
that would explain this result, we cannot rule out that the glycosylation of the human PrP was responsible. For 
this reason, we used the mouse model TgNN6h to determine the abilities of the same misfolded prion proteins 
to propagate in vitro over an unglycosylated human prion protein. Both samples (brain and in vitro derived) were 
able to propagate in this new model in vitro suggesting that, apart from the existence of a transmission barrier 
due to the similarity between primary sequences of PrPs, there seems to be other barriers governed by the state of 
glycosylation of both proteins (seed and substrate). The PrP protein expressed in TgNN6h transgenic mice carries 
the N181Q and N197Q mutations that prevent glycosylation. To determine whether these amino acid changes 
could interfere with propagation of the misfolded protein, a homologous recombinant protein was generated and 
its propagation ability was studied using different seeds. Amino acid substitutions did not decrease the propa-
gation efficiency of the protein compared to the human wild type recombinant prion protein (data not shown). 
Since P102L-129M misfolded rec-PrP protein propagated efficiently by brain-PMCA in a substrate containing 
unglycosylated human PrP but containing a GPI anchor, we wanted to see if this efficient propagation could 
take place using other misfolded rec-PrPs. Hence, the rest of the misfolded proteins were subjected to 10 serial 
rounds of recPMCA. While P102L-129V and A117V-129M and A117V-129V misfolded rec-PrPs needed just 
three rounds to overcome the brain/recombinant barrier, the A117V-129V misfolded rec-PrP needed 10 rounds. 
These results confirmed, once again, the existence of differences, likely structural, between all the spontaneously 
generated misfolded proteins that confer on them a priori unpredictable propagation behaviour in different in 
vitro or animal models.
As predicted by brain-PMCA, neither in vitro GSS-related rec-PrP nor GSS from a human patient showed 
evidences of in vivo propagation in the humanized transgenic mouse model (Tg340). These results confirmed 
the difficulties of this atypical human prion strain to be transmitted in its homologous or evolutionarily closely 
related (primate) species12. However, the ability of prions to be adapted to other species led us to use the Tga20 
mouse model as it is one of the best characterized models in the prion field. Recent studies have confirmed that 
correct evaluation of transmissibility and/or infectivity of certain prion strains should be performed in proper 
animal models (with a demonstrated susceptibility to the kind of prion tested), even if these are not expressing 
homologous PrP11.
The high attack rates obtained after the inoculation of both in vitro and in vivo GSS-derived samples indicates 
undoubtedly the capacity of this model to propagate the human atypical prion strain. Indistinguishable atypical 
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electrophoretic patterns obtained from both samples after PK digestion of inoculated mouse brains strongly 
demonstrates the generation of an infectious recombinant prion.
Now that our in vitro and in vivo results have evaluated extensively one of our misfolded recombinant prion 
proteins, we wish to highlight the advantages of using recPMCA in determining the proneness to misfolding of 
certain pathogenic prion protein mutations along with their use to improve the understanding of the spontaneous 
misfolding process underlying many TSEs.
Methods
Preparation of purified recombinant PrPs. The bacterial expression of the human recombinant 
PrPs (rec-PrPs) was performed using expression vectors prepared by standard molecular biology tech-
niques. Specifically, pOPIN vectors developed by Oxford Protein Production Facility UK (OPPF) were used 
to introduce the wild type 129M and 129V human PRNP genes by homologous recombination using the In 
Fusion cloning method72. Briefly, pOPIN E vector was digested with NcoI and PmeI restriction enzymes 
(New England Laboratories) according to the protocol specified by OPPF (A Guide to using the OPPF pOPIN 
Vector suite for HTP In-Fusion Cloning) and it was purified for homologous recombination with the frag-
ment containing the ORF (23–231) of 129M and 129V human PRNP genes, previously obtained by 
PCR using the oligonucleotides 5′ AGGAGATATACCATGAAGAAGCGCCCGAAGCCTGG 3′ and 5′ 
GTGATGGTGATGTTAGCTCGATCCTCTCTGGTAATA 3′. All the genetic constructs containing the 
human TSE-related mutations were generated by site-directed mutagenesis using QuikChange II Site-Directed 
Mutagenesis Kit and following the user protocol (Agilent Technologies). The oligonucleotide pairs used to intro-
duce the nucleotide change are listed in the Supplementary Table 2.
The expression vectors were transformed in E. coli Rosetta™ (DE3) Competent Cells (EMD Millipore) 
using standard molecular biology procedures allowing the expression of the corresponding recombinant pro-
teins. Briefly, the bacterial pellet obtained after the induction of 1 L of culture with IPTG (final 1 mM) (Gold 
Biotechnology) was resuspended in 50 ml of lysis buffer [50 mM tris(hydroxymethyl)aminomethane hydro-
chloride Tris-HCl (Fisher Bioreagents), 5 mM ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich), 1% 
Triton X-100 (Amresco), 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich), 100 µg/ml lysozyme 
(Sigma-Aldrich), pH 8.0] and then incubated for 30 min with stirring at 200 rpm at room temperature in the 
presence of 100 U/ml deoxyribonuclease (DNase) (Sigma-Aldrich) and 20 mM magnesium chloride (MgCl2) 
(Sigma-Aldrich). The lysate was centrifuged at 4 °C for 1 h at 8,500 g (Sorvall ST 16 R, Thermo Scientific) and 
the resulting pellet was resuspended in 50 ml of washing buffer [20 mM Tris-HCl (Fisher Bioreagents), 150 mM 
sodium chloride (NaCl) (Sigma-Aldrich), 1 mM EDTA (Sigma-Aldrich), 1% Sarkosyl (Sigma-Aldrich), pH 8.0]. 
The lysate was centrifuged under the conditions described above and the pellet was dissolved in 6 ml of inclusion 
buffer [20 mM Tris-HCl (Fisher Bioreagents), 0.5 M NaCl (Sigma-Aldrich), 6 M GdnHCl (Fisher Scientific), pH 
8.0] and incubated at 37 °C, with stirring, overnight in order to dissolve the inclusion bodies and solubilise the 
recombinant protein in the medium. Samples were centrifuged at 4 °C for 1 h at 8,500 g and the supernatants fil-
tered through 0.20 µm pore size (Minisart, Sartorius Stedim) before purification.
The purification of the recombinant proteins was performed with a histidine affinity column (5 ml HisTrap 
Crude FF; GE Healthcare Amersham). The column was equilibrated with 35 ml of binding buffer [20 mM 
Tris-HCl (Fisher Bioreagents), 500 mM NaCl (Sigma-Aldrich), 5 mM imidazole (Sigma-Aldrich), 2 M GdnHCl 
(Fisher Scientific), pH 8.0] and the filtered sample containing the soluble recombinant PrP was loaded onto the 
column using needles (22 G gauge by 1 ¼ inches length, Terumo). The column was washed with 75 ml of bind-
ing buffer and the recombinant protein eluted with 30 ml elution buffer [20 mM Tris-HCl (Fisher Bioreagents), 
500 mM NaCl (Sigma-Aldrich), 500 mM imidazole (Sigma-Aldrich), 2 M GdnHCl (Fisher Scientific), pH 8.0]. 
The eluted proteins were denatured by addition of GdnHCl (Sigma-Aldrich) to a final concentration of 6 M and 
then concentrated to 4–5 mg/ml using 10 kDa centrifugal filter units (Amicon Ultra-15 10 kDa Centrifugal filter 
unit, Millipore). The recombinant proteins were stored at −20 °C until required. The quality and purity were 
assessed by Coomassie blue staining after electrophoresis in a 4–15% or 4–12% sodium dodecyl sulfate poly-
acrylamide gel (SDS-PAGE).
Preparation of PMCA substrates. Standard PMCA was performed using substrates based on whole 
brain homogenates from two transgenic mouse lines as previously described48. Tg340 transgenic mouse line 
that expresses 4 fold human PrPC45 and TgNN6h transgenic mouse line that expressed one fold non-glycosylated 
human PrPC46 were used.
Recombinant based PMCA (recPMCA) was performed using substrates based on purified recombinant pro-
teins supplemented with brain homogenates from Prnp0/0 transgenic mice73. Firstly, the recombinant proteins 
were diluted 1:5–1:10 in PBS (Fisher Bioreagents) and dialyzed against PBS at 4 °C for 1 h using 10 KDa dialysis 
cassettes (Slide-A-Lyzer Dialysis Cassette MWCO 10 K, Thermo Scientific). To remove the insoluble abnormally 
folded protein generated as a result of the dialysis process, samples were centrifuged at 19,000 g for 15 min at 4 °C 
(Sorvall ST 16 R, Thermo Scientific) and the supernatant containing soluble protein was collected. The dialyzed 
protein was mixed in 1:100 (v:v) ratio with brain homogenate from Prnp0/0 transgenic mice which had been 
perfused as described previously48. Briefly, brains were homogenized at 10% (w/v) in conversion buffer at 4 °C 
and centrifuged at 19,000 g for 15 min at 4 °C (Sorvall ST 16 R, Thermo Scientific). The supernatant was mixed 
with the PrP recombinant protein previously measured by BCA Protein Assay (Thermo Pierce) to achieve a final 
concentration of 50–100 ng/µl.
Mouse liver RNA-complemented recombinant based PMCA substrate was prepared using RNA extracted 
from Prnp0/0 transgenic mice liver mixed with rec-PrP dialyzed as described previously. For the RNA extraction, 
the livers were homogenized in RNAzol RT (Sigma-Aldrich) and chloroform was added. The homogenates were 
centrifuged at 19,000 g for 15 min at 4 °C and the aqueous phase washed with isopropanol. Finally, the pellet was 
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washed with 70% (v/v) ethanol, air-dryed and resuspended in nuclease-free water (Amresco). The final substrate 
was prepared mixing dyalized rec-PrP measured as previously by BCA protein assay, conversion buffer and RNA 
up to 6 mg/ml.
In vitro propagation of prions by PMCA. The in vitro prion propagation studies were performed based on 
modified versions of the PMCA described previously37, 48, 74. Briefly, both brain- and recombinant based PMCAs 
were conducted in 0.2 ml tubes with a final volume of 50 µl. The sonicator model and the parameters used during 
sonication were specific for each type of PMCA:
recPMCA. Q-700 Misonix sonicator with microplate system (Qsonica) was used with incubation cycles of 
30 min, followed by sonication pulses of 15 s at 50–60% power. The whole process was carried out at an average 
temperature of 39 °C regulated by a circulating water bath.
Brain-PMCA. S-4000 Misonix sonicator with microplate system (Qsonica) was used with incubation cycles of 
30 min, followed by sonication pulses of 20 s at 80% power. The whole process was carried out at an average tem-
perature of 37 °C regulated by a circulating water bath.
Three different types of studies were performed:
Prion amplification by serial dilutions. Serial dilutions of the seed were subjected to one-round of PMCA (24–
48 h) and the proteinase-K (PK)-resistant signal obtained by Western blot was compared to the non-amplified 
seed. Reproducibility of the results was ensured by using 1 mm zirconia/silica beads (BioSpec Products)69.
Continuous amplification and transmission barrier studies. The in vitro ability of prions to adapt to new hosts or 
to maintain the strain characteristics along passages was carried out by performing successive rounds of PMCA 
where prion strains were diluted 1:5–1:10 in the corresponding substrate. After a round of 24–48 h PMCA, ampli-
fied sample from the first round was diluted 1:10 in fresh substrate and the process was repeated for another 
10–30 rounds of PMCA.
Generation of spontaneous misfolded proteins. The spontaneous misfolding ability of different recombinant PrPs 
was assessed by recPMCA in an identical manner to that given in the previous section but without adding any 
seed.
All the procedures described in this section were performed within a biosafety level 3 laboratory, handling 
human samples, both brain-derived and recombinant in a biosafety hood.
Biochemical characterization of in vitro- and in vivo-generated prion strains. Protease resistance 
assay. recPMCA treated samples were incubated with 25 µg/ml of PK (Roche) for 1 h at 42 °C and constant 
agitation of 450 rpm (Thermomixer comfort Eppendorf). Samples were mixed previously 1:1 (v:v) with 10% 
Sarkosyl (Sigma-Aldrich) digestion buffer and the digestion was stopped by adding electrophoresis Laemmli 
buffer NuPAGE (Invitrogen Life Technologies). In case of mammalian PrPSc, 50–100 µg/ml of PK and 2% Tween-
20 (Sigma-Aldrich) + 2% Nonidet P40 (Sigma-Aldrich) digestion buffer were used. In other exceptional cases in 
which different amounts of PK were used, it will be listed individually.
PK-resistant PrP detection and quantification. Protein immunodetection by Western blot (WB) was performed 
after separating proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). TGX 
Criterion 4–15% gel (Bio-Rad) was used for misfolded rec-PrP samples and 4–12% NuPAGE Midi gel (Invitrogen 
Life Technologies) for mammalian samples. The recombinant proteins were electroblotted onto polyvinylidene 
fluoride (PVDF) membranes (Trans-Blot Transfer Pack Turbo PVDF, Bio-Rad) and the mammalian proteins 
onto nitrocellulose membranes (Protran BA85, GE Healthcare). Membranes were probed with antibody 3F4 
(diluted 1:10,000 in 0.1% (w/v) of fat-free powder milk in phosphate buffered saline (PBS, Fisher Bioreagents) 
with 0.05% Tween-20 (Sigma-Aldrich, Atom) as described previously75. The immunoreactive bands were visual-
ized by chemiluminescence using the Super Signal West Pico kit (Thermo Scientific Pierce) and the digital images 
were recorded by FluorChem Q (Alpha Innotech).
Densitometric analysis of the immunoreactive bands obtained by WB was carried out using the AlphaView 
software (Alpha Innotech). The images were analysed by densitometry to evaluate the relative amount of immu-
noreactive band signal strength, quantified in terms of optical density and translated to percentages.
Detection of atypical PrPres. The detection of PK-resistant PrP from inoculated mouse brains was performed 
following two different protocols: i) a standard procedure as described above and ii) an adapted protocol devel-
oped to detect atypical PrPSc. Briefly, 40 μl of 10% brain homogenate were diluted in 160 μl phosphate buff-
ered saline (PBS, Fisher Bioreagents) and digested with 12.5 μg of PK in digestion buffer (8% Sarkosyl and 5% 
sodium dodecylsulfate in PBS). The sample was incubated for 15 min at 37 °C with constant agitation at 500 rpm 
(Thermomixer comfort, Eppendorf) and then sonicated for 8 × 30 seconds (Misonix Sonicator Q-700 microplate 
system, Qsonica). The sample was mixed with 200 μl of butanol (Sigma-Aldrich) and centrifuged for 7 min at a 
15,000 g (5415D centrifuge, Eppendorf). The supernatant was removed and the pellet resuspended and incubated 
5 min at room temperature with 50 μl of Laemmli loading buffer (Bio-Rad). Before loading, the samples were 
incubated for 5 min at 100 °C, centrifuged for 15 min at 15,000 g and the supernatants collected for further analy-
sis by Western blotting as described above using 12B2 antibody [diluted 1:2,500 in 0.1% (w/v) of fat-free powder 
milk in PBS (Fisher Bioreagents) with 0.05% Tween-20 (Sigma-Aldrich)].
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Tris/tricine electrophoresis and Western blot. Three hundred µl of misfolded rec-PrPs were treated with 25 μg/
ml of PK for 1 h at 42 °C and 450 rpm agitation (Thermomixer Comfort, Eppendorf). The reaction was stopped 
by addition of 2 mM Pefabloc (Fluka) to a final concentration of 2 mM and incubation on ice for 15 min. Sample 
was centrifuged at 18,000 g for 1 h at 4 °C and the resultant pellet resuspended in GdnHCl 6 M. PK-resistant pep-
tides were precipitated with ice-cold 85% methanol. The resultant precipitate was resuspended in 10 µl of MiliQ 
H2O and 10 μl Tricine sample buffer (BioRad) with 2% (v:v) β-mercaptoethanol (Sigma-Aldrich). Samples were 
then subjected to tris/tricine electrophoresis as described previously63. The gel was stained with Coomassie blue 
stain or, alternatively, transferred to Immobilon P 0.45 µm PVDF membranes, which were subsequently probed 
with antibody 12B2, which recognises PrP epitope 90–9238, at a 1:1,000 dilution. Goat anti-mouse antibody (GE 
Healthcare Life Science) conjugated with horseradish peroxidase was used as secondary antibody diluted 1:5,000. 
Immunoreactive fragments were visualized by chemiluminescence using ECL-plus reagent (GE Healthcare).
All studies described in this section were carried out in a biosafety level 3 laboratory under strict biocontain-
ment measures, including handling of samples within a biosafety cabinet and waste disposal after treatment with 
NaOH 1 N and autoclaving at 134 °C.
Analysis by electron microscopy (EM). Transmission electron microscopy. Misfolded recombinant sam-
ples were deposited in freshly glow-discharged carbon-coated gold grids (Electron Microscopy Sciences), washed 
with deionised (d.i) H20 and stained with freshly prepared, filtered 5% uranyl acetate.
Cryo-electron microscopy. Misfolded recombinant samples were concentrated up to 100 fold previous to their 
analysis by cryo-electron microscopy. 1 ml of each sample was digested with PK (100 µg/ml) for 1 h at 42 °C 
and 550 rpm agitation (Thermomixer comfort, Eppendorf). Samples were centrifuged immediately for 1 h at 
19,000 g and 4 °C (Sorvall ST 16 R, Thermo Scientific). The resultant pellet was resuspended in 10 µl PBS (Fisher 
Bioreagents) and stored at −20 °C until microscopic examination.
The sample was applied directly to a carbon-coated grid, R 2/2 Quantifoil® (Quantifoil), and rapidly plunged 
into liquid ethane with the help of Vitrobot (Maastricht Instruments BV). Sample analysis was carried out with a 
JEM 2200 F (JEOL) transmission cryo-electron microscope, using an acceleration voltage of 200 KV and defocus 
ranging from 21.2 to 22.5 mm, determined accurately by using enhanced power spectra. Images were taken with 
2k62k TM Ultrascan 1000 CCD camera (Gatan)76.
GPI-anchorless PrPSc was isolated from RML-infected GPI-anchorless PrP Tg mice and imaged by cryoEM 
as reported previously63, 77.
In vivo characterization in transgenic mouse models. Preparation of in vivo and in vitro derived inoc-
ula. 10% brain homogenate from GSS affected patient and PMCA misfolded GSS-related rec-PrP were diluted 
10−1 in sterile PBS previous to their intracerebral inoculation.
Animal inoculations. 4–6 weak old mice from two different transgenic mouse lines: Tg34045 and Tga2047 were 
anesthetized with isoflurane and then inoculated in the parietal cortex with 20 µl of inoculum using a sterile 
disposable 27-gauge hypodermic needle. Mice were kept in a controlled environment at a room temperature of 
22 °C, 12 h light-darkness cycle and 60% relative humidity in HEPA filtered cages (both air inflow and extrac-
tion) in ventilated racks. The mice were fed ad libitum, observed daily and their clinical status assessed twice 
a week. The presence of ten different TSE-associated clinical signs [48] was scored. When progression of the 
clinical disease was evident, the animals were euthanized, for ethical reasons, by cervical dislocation or CO2 
inhalation immediately prior to biological sampling. Positive TSE diagnosis relied principally on the detection of 
PK-resistant PrP by Western blotting and associated spongiform change in the brain parenchyma.
The procedures described in this section including inoculations, animal maintenance, culling and sample 
processing were carried out in a biosafety level 3 facility.
Ethics statement. All animal experiments were performed in compliance with institutional and French 
national guidelines and in accordance with the European Community Council Directive 86/609/EEC. The ani-
mal experiments that are part of this study (national registration 01734.01) were approved by the ENVT (École 
Nationale Vétérinaire de Toulouse) ethic committee.
GSS affected patient samples were collected directly from the Biobank IDIBAPS (http://www.idibaps.org/) and 
from the tissue bank of University Hospital Complex of Vigo.
References
 1. Aguzzi, A. Prion diseases of humans and farm animals: epidemiology, genetics, and pathogenesis. J Neurochem 97, 1726–1739 
(2006).
 2. Prusiner, S. B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136–144 (1982).
 3. Collinge, J. Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry 76, 906–919 (2005).
 4. Imran, M. & Mahmood, S. An overview of human prion diseases. Virol J 8, 559 (2011).
 5. Gambetti, P., Kong, Q., Zou, W., Parchi, P. & Chen, S. G. Sporadic and familial CJD: classification and characterisation. Br Med Bull 
66, 213–239 (2003).
 6. Colby, D. W. & Prusiner, S. B. Prions. Cold Spring Harb Perspect Biol 3, a006833 (2011).
 7. Masters, C. L. et al. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic 
clustering. Ann Neurol 5, 177–188 (1979).
 8. Schumm, F., Boellaard, J. W., Schlote, W. & Stohr, M. [Morbus Gerstmann-Straussler-Scheinker. The Sch. family-a report of three 
cases (author’s transl)]. Arch Psychiatr Nervenkr 230, 179–196 (1981).
 9. Lugaresi, E. et al. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med 315, 
997–1003 (1986).
www.nature.com/scientificreports/
17Scientific RepoRts | 7: 9584  | DOI:10.1038/s41598-017-09489-3
 10. Watts, J. C. et al. Towards authentic transgenic mouse models of heritable PrP prion diseases. Acta Neuropathol (2016).
 11. Pirisinu, L. et al. Gerstmann-Straussler-Scheinker disease subtypes efficiently transmit in bank voles as genuine prion diseases. Sci 
Rep 6, 20443 (2016).
 12. Baker, H. F., Duchen, L. W., Jacobs, J. M. & Ridley, R. M. Spongiform encephalopathy transmitted experimentally from Creutzfeldt-
Jakob and familial Gerstmann-Straussler-Scheinker diseases. Brain 113(Pt 6), 1891–1909 (1990).
 13. Asante, E. A. et al. Inherited prion disease A117V is not simply a proteinopathy but produces prions transmissible to transgenic mice 
expressing homologous prion protein. PLoS Pathog 9, e1003643 (2013).
 14. Pirisinu, L. et al. Small ruminant nor98 prions share biochemical features with human gerstmann-straussler-scheinker disease and 
variably protease-sensitive prionopathy. PLoS One 8, e66405 (2013).
 15. Bessen, R. A. & Marsh, R. F. Biochemical and physical properties of the prion protein from two strains of the transmissible mink 
encephalopathy agent. J Virol 66, 2096–2101 (1992).
 16. Bessen, R. A. & Marsh, R. F. Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters. J 
Gen Virol 73(Pt 2), 329–334 (1992).
 17. Hsiao, K. K. et al. Spontaneous neurodegeneration in transgenic mice with mutant prion protein. Science 250, 1587–1590 (1990).
 18. Telling, G. C. et al. Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. 
Genes Dev 10, 1736–1750 (1996).
 19. Manson, J. C. et al. A single amino acid alteration in murine PrP dramatically alters TSE incubation time. Arch Virol Suppl, 95–102 
(2000).
 20. Torres, J. M. et al. Spontaneous generation of infectious prion disease in transgenic mice. Emerg Infect Dis 19, 1938–1947 (2013).
 21. Friedman-Levi, Y. et al. Fatal prion disease in a mouse model of genetic E200K Creutzfeldt-Jakob disease. PLoS Pathog 7, e1002350 
(2011).
 22. Jackson, W. S. et al. Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice. Neuron 63, 438–450 (2009).
 23. Bouybayoune, I. et al. Transgenic fatal familial insomnia mice indicate prion infectivity-independent mechanisms of pathogenesis 
and phenotypic expression of disease. PLoS Pathog 11, e1004796 (2015).
 24. Legname, G. et al. Synthetic mammalian prions. Science 305, 673–676 (2004).
 25. Deleault, N. R., Harris, B. T., Rees, J. R. & Supattapone, S. Formation of native prions from minimal components in vitro. Proc Natl 
Acad Sci USA 104, 9741–9746 (2007).
 26. Bocharova, O. V., Breydo, L., Salnikov, V. V., Gill, A. C. & Baskakov, I. V. Synthetic prions generated in vitro are similar to a newly 
identified subpopulation of PrPSc from sporadic Creutzfeldt-Jakob Disease. Protein Sci 14, 1222–1232 (2005).
 27. Legname, G. et al. Strain-specified characteristics of mouse synthetic prions. Proc Natl Acad Sci USA 102, 2168–2173 (2005).
 28. Chu, N. K. & Becker, C. F. Semisynthesis of membrane-attached prion proteins. Methods Enzymol 462, 177–193 (2009).
 29. Kim, J. I. et al. Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. J 
Biol Chem 285, 14083–14087 (2010).
 30. Colby, D. W. et al. Protease-sensitive synthetic prions. PLoS Pathog 6, e1000736.
 31. Wang, F., Wang, X., Yuan, C. G. & Ma, J. Generating a prion with bacterially expressed recombinant prion protein. Science 327, 
1132–1135 (2010).
 32. Wang, F., Wang, X. & Ma, J. Conversion of bacterially expressed recombinant prion protein. Methods 53, 208–213 (2011).
 33. Saa, P., Castilla, J. & Soto, C. Cyclic amplification of protein misfolding and aggregation. Methods Mol Biol 299, 53–65 (2005).
 34. Hamasaki, S. et al. Discordant Gerstmann-Straussler-Scheinker disease in monozygotic twins. Lancet 352, 1358–1359 (1998).
 35. Webb, T. et al. Seven-year discordance in age at onset in monozygotic twins with inherited prion disease (P102L). Neuropathol Appl 
Neurobiol 35, 427–432 (2009).
 36. Prusiner, S. B. Prions. Proc Natl Acad Sci USA 95, 13363–13383 (1998).
 37. Saa, P., Castilla, J. & Soto, C. Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J 
Biol Chem 281, 35245–35252 (2006).
 38. Choi, J. K. et al. Generation of monoclonal antibody recognized by the GXXXG motif (glycine zipper) of prion protein. Hybridoma 
(Larchmt) 25, 271–277 (2006).
 39. Terry, C. et al. Ex vivo mammalian prions are formed of paired double helical prion protein fibrils. Open Biol 6 (2016).
 40. Sim, V. L. & Caughey, B. Ultrastructures and strain comparison of under-glycosylated scrapie prion fibrils. Neurobiol Aging 30, 
2031–2042 (2009).
 41. Piro, J. R. et al. Seeding specificity and ultrastructural characteristics of infectious recombinant prions. Biochemistry 50, 7111–7116 
(2011).
 42. Timmes, A. G., Moore, R. A., Fischer, E. R. & Priola, S. A. Recombinant prion protein refolded with lipid and RNA has the 
biochemical hallmarks of a prion but lacks in vivo infectivity. PLoS One 8, e71081 (2013).
 43. Cortez, L. M., Kumar, J., Renault, L., Young, H. S. & Sim, V. L. Mouse prion protein polymorphism Phe-108/Val-189 affects the 
kinetics of fibril formation and the response to seeding: evidence for a two-step nucleation polymerization mechanism. J Biol Chem 
288, 4772–4781 (2013).
 44. Kurt, T. D., Telling, G. C., Zabel, M. D. & Hoover, E. A. Trans-species amplification of PrP(CWD) and correlation with rigid loop 
170N. Virology 387, 235–243 (2009).
 45. Padilla, D. et al. Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. PLoS Pathog 7, 
e1001319 (2011).
 46. Haldiman, T. et al. Co-existence of distinct prion types enables conformational evolution of human PrPSc by competitive selection. 
J Biol Chem 288, 29846–29861 (2013).
 47. Fischer, M. et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO 
J 15, 1255–1264 (1996).
 48. Castilla, J., Saa, P., Hetz, C. & Soto, C. In vitro generation of infectious scrapie prions. Cell 121, 195–206 (2005).
 49. Baskakov, I. V. The reconstitution of mammalian prion infectivity de novo. FEBS J 274, 576–587 (2007).
 50. Choi, J. K. et al. Amyloid fibrils from the N-terminal prion protein fragment are infectious. Proc Natl Acad Sci USA 113, 
13851–13856 (2016).
 51. Masel, J., Jansen, V. A. & Nowak, M. A. Quantifying the kinetic parameters of prion replication. Biophys Chem 77, 139–152 (1999).
 52. Baskakov, I. V. Branched chain mechanism of polymerization and ultrastructure of prion protein amyloid fibrils. FEBS J 274, 
3756–3765 (2007).
 53. Jeong, B. H. & Kim, Y. S. Genetic studies in human prion diseases. J Korean Med Sci 29, 623–632 (2014).
 54. Jackson, W. S. et al. Profoundly different prion diseases in knock-in mice carrying single PrP codon substitutions associated with 
human diseases. Proc Natl Acad Sci USA 110, 14759–14764 (2013).
 55. Asante, E. A. et al. Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant 
human prion proteins. J Gen Virol 90, 546–558 (2009).
 56. Noble, G. P., Walsh, D. J., Miller, M. B., Jackson, W. S. & Supattapone, S. Requirements for mutant and wild-type prion protein 
misfolding in vitro. Biochemistry 54, 1180–1187 (2015).
 57. Collinge, J. & Palmer, M. S. Molecular genetics of human prion diseases. Philos Trans R Soc Lond B Biol Sci 343, 371–378 (1994).
 58. Alzualde, A. et al. A novel PRNP Y218N mutation in Gerstmann-Straussler-Scheinker disease with neurofibrillary degeneration. J 
Neuropathol Exp Neurol 69, 789–800 (2010).
www.nature.com/scientificreports/
1 8Scientific RepoRts | 7: 9584  | DOI:10.1038/s41598-017-09489-3
 59. Dossena, S. et al. Mutant prion protein expression causes motor and memory deficits and abnormal sleep patterns in a transgenic 
mouse model. Neuron 60, 598–609 (2008).
 60. Yang, W. et al. A New Transgenic Mouse Model of Gerstmann-Straussler-Scheinker Syndrome Caused by the A117V Mutation of 
PRNP. J Neurosci 29, 10072–10080 (2009).
 61. Parchi, P. et al. Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-
Straussler-Scheinker disease. Proc Natl Acad Sci USA 95, 8322–8327 (1998).
 62. Tagliavini, F. et al. A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the 
major amyloid protein in Gerstmann-Straussler-Scheinker disease A117V. J Biol Chem 276, 6009–6015 (2001).
 63. Vazquez-Fernandez, E. et al. Structural organization of mammalian prions as probed by limited proteolysis. PLoS One 7, e50111 
(2012).
 64. Chesebro, B. et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308, 1435–1439 
(2005).
 65. Prusiner, S. B. et al. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 
63, 673–686 (1990).
 66. Scott, M. et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. 
Cell 59, 847–857 (1989).
 67. Scott, M. et al. Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell 73, 979–988 
(1993).
 68. Brown, P. et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally 
transmitted disease. Ann Neurol 35, 513–529 (1994).
 69. Fernandez-Borges, N., de Castro, J. & Castilla, J. In vitro studies of the transmission barrier. Prion 3, 220–223 (2009).
 70. Castilla, J. et al. Crossing the species barrier by PrP(Sc) replication in vitro generates unique infectious prions. Cell 134, 757–768 
(2008).
 71. Castilla, J. et al. Cell-free propagation of prion strains. EMBO J 27, 2557–2566 (2008).
 72. Berrow, N. S. et al. A versatile ligation-independent cloning method suitable for high-throughput expression screening applications. 
Nucleic Acids Res 35, e45 (2007).
 73. Manson, J. C. et al. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol 
Neurobiol 8, 121–127 (1994).
 74. Saborio, G. P., Permanne, B. & Soto, C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. 
Nature 411, 810–813 (2001).
 75. Kascsak, R. J. et al. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 61, 3688–3693 (1987).
 76. Gonzalez, E. et al. Human mammospheres secrete hormone-regulated active extracellular vesicles. PLoS One 9, e83955 (2014).
 77. Baron, G. S. et al. Effect of glycans and the glycophosphatidylinositol anchor on strain dependent conformations of scrapie prion 
protein: improved purifications and infrared spectra. Biochemistry 50, 4479–4490 (2011).
Acknowledgements
This work was supported financially by Spanish government grants AGL2015-65046-C2-1-R, PCIN-2013-065 
and BFU2013-48436-C2-1-P and Basque government grant 2014111157. The authors would like to thank the 
following for their support: IKERBasque foundation, vivarium and maintenance from CIC bioGUNE. Oxford 
Protein Production Facility UK (OPPF) for the plasmid pOPIN E, Dr. Belén Pintado for the TgNN6h mouse 
embryo rederivation, Dr. Ester Vázquez Fernández for useful advice in the initial steps, Drs. Isidro Ferrer and 
Carmen Navarro for the GSS brain tissue samples. Mark P. Dagleish (Moredun Research Institute) for useful 
discussion and advice.
Author Contributions
J.C., S.R.E. and N.F.B. conceived the experiments, S.R.E., N.F.B., H.E., A.M.S., J.M.C., C.H., P.S., D.G., Q.K. and 
O.A. conducted the experiments, J.C., S.R.E. and N.F.B. analysed the results and J.C., S.R.E., H.E. and J.R.R. wrote 
and reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-09489-3
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
